Opinion
Video
Navigating Treatment Options in mCSPC: Choosing the Right Doublet or Triplet Therapy
Author(s):
Key Takeaways
- Management of mCSPC involves ADT combined with systemic therapies like docetaxel, abiraterone, enzalutamide, or apalutamide.
- These combination therapies improve overall survival and progression-free survival in mCSPC patients.
Panelists discuss how guideline-recommended treatment options for metastatic castration-sensitive prostate cancer (mCSPC) include various combinations of androgen deprivation therapy, docetaxel, and novel hormonal agents, tailored to the patient’s disease characteristics and overall health.
Video Player is loading.
Video content above is prompted by the following:
- What are the guideline-recommended treatment options for patients with mCSPC (“castration-naive” CSPC)?
Related Videos
Managing Cognitive and Sexual Health in Prostate Cancer Patients on Hormonal Therapy
Innovative Treatment Strategies in High-Risk Biochemical Recurrence: Insights From the EMBARK Trial
Managing Biochemical Recurrence in Prostate Cancer: Risk Stratification and Treatment Decisions
Overcoming Unmet Needs in Treating mCSPC: ADT Monotherapy vs Multimodal Approaches
Defining mCSPC: Diagnostic Criteria, Imaging Approaches, and Patient Identification
Emerging Trends and Rising Prevalence of mCSPC
Related Content
